Revenue growth and expanding installed base are positive, but profitability remains distant. Watch for CAPTAIN trial data at EAU Congress (March 13) as a key catalyst. The stock may react positively to clinical validation, but sustained execution and margin improvement will be needed for long-term upside.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 6 $5.31entry
- T+1 · 8mo ago −1.51%α −2.35% · $5.23
- T+5 · 8mo ago +3.77%α +5.29% · $5.51
- T+20 · 8mo ago +23.54%α +25.58% · $6.56
- T+60 · 6mo ago +25.61%α +12.83% · $6.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Profound Medical reported record Q4 and full-year 2025 results, with Q4 revenue up 43% YoY to $6.0 million, driven by strong capital equipment sales and recurring revenue. The company strengthened its balance sheet with a $42.45 million equity raise, expanded globally through new distribution deals, and launched AI-enhanced TULSA-AI for BPH. Despite revenue growth, net losses widened to $8.2M in Q4 and $42.6M for the year due to rising operating expenses.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $6.0 million, up 43% YoY ($4.2M in Q4 2024)
- Full-year 2025 revenue: $16.1 million vs. $10.7 million in 2024
- Gross margin: 67% in Q4 2025 (down from 71% YoY), 71% for full-year 2025 (up from 66%)
- Net loss: $8.2 million in Q4 2025 vs. $4.9 million in Q4 2024; $42.6 million for FY2025 vs. $27.8 million in FY2024
- Cash balance: $59.7 million as of Dec 31, 2025, after $36.0M US registered direct and $6.45M Canadian private placement
- TULSA-PRO installed base: 78 systems as of Dec 31, 2025; guidance for ~120 by end of 2026
- Launched TULSA-AI Volume Reduction module for BPH, aiming to triple total addressable market to ~600,000 patients annually
- Frank Baylis appointed to Board; successor to Kris Shah
Financial Impact
Revenue grew 50.5% in 2025 to $16.1M, but net loss increased by $14.8M. Operating expenses rose 31% to $52.6M. Positive cash flow from financing ($41.1M) offset operating cash burn ($38.2M).
Risk Factors
- Widening net losses despite revenue growth indicate high cost structure
- Dependence on capital equipment sales creates revenue volatility
- Future profitability hinges on scaling recurring revenue and controlling OpEx
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250672 |
Track record
22 reports on PROF
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +25.61% at T+60 after the Mar 5, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $7.44 Now $7.34 −1.34% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $7.34 Now $7.34 +0.00% settles Dec 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.21 Now $7.34 −1.80% settles Dec 7
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $7.16 Now $7.34 +2.51% settles Dec 3
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $6.57 Now $7.34 +11.72% settles Nov 30
- Oct 22, 202625d ago 8-K Neutral 2/10 Entry $5.56 Now $7.34 +32.01% settles Nov 20
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $6.62 to $7.68 Now $7.34 +10.88% ▲ +16.01% +18.57% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $6.90 to $7.01 Now $7.34 +6.38% ▲ +1.59% +7.15% vs SPY
- Oct 7, 20265w ago 8-K Bullish 7/10 Entry $6.91 to $7.16 Now $7.34 +6.22% ▲ +3.62% +8.91% vs SPY
- Sep 3, 202610w ago 8-K Neutral 2/10 Entry $6.89 to $6.03 Now $7.34 +6.53% ▼ −12.48% −13.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers